Maternal liver-related symptoms during pregnancy in primary sclerosing cholangitis.

Bile acids Cholangiopathy Intrahepatic cholestasis of pregnancy Primary sclerosing cholangitis Pruritus Ursodeoxycholic acid

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 03 08 2023
revised: 04 10 2023
accepted: 17 10 2023
medline: 13 12 2023
pubmed: 13 12 2023
entrez: 13 12 2023
Statut: epublish

Résumé

Although worsening liver-related symptoms during pregnancy can occur in primary sclerosing cholangitis (PSC), there are insufficient data to effectively counsel patients on their pre-conception risk and no clear recommendations on monitoring and management during pregnancy. We aimed to describe maternal liver-related symptoms in pregnancy, both before and after PSC diagnosis, and explore factors associated with worsening symptoms and liver-related outcomes. We conducted a multicentre retrospective observational study of females with PSC and known pregnancy with live birth, via the International PSC Study Group. We included 450 patients from 12 European centres. Data included clinical variables, liver-related symptoms (pruritus and/or cholangitis) during pregnancy, and liver biochemistry. A composite primary endpoint of transplant-free survival from time of PSC diagnosis was used. There were 266 pregnancies in 178 patients following PSC diagnosis. Worsening liver-related symptoms were reported in 66/228 (28.9%) pregnancies; they had a reduced transplant-free survival ( Liver-related symptoms are frequently encountered during pregnancies before the diagnosis of PSC, and pregnancy may expose the pre-clinical phase of PSC in some patients. Worsening liver-related symptoms were seen in a third of our cohort with known PSC during pregnancy; and this subgroup had a poorer prognosis, which may be related to more advanced liver disease at time of pregnancy and/or a more severe disease phenotype. Patients with PSC can develop worsening of their liver-related symptoms during pregnancy; however, risk factors for this and the long-term implications are not known. We identified that there is a significant risk of these symptoms in pregnancy, both before and after PSC has been diagnosed, particularly in patients with elevated alkaline phosphatase. Furthermore, our findings suggest that worsening symptoms during pregnancy may be associated with adverse long-term clinical outcomes of liver transplantation and death in patients with known PSC. This may be related to the presence of more advanced liver disease at time of pregnancy. This information can be used to counsel patients with PSC before conception and identify patients who need close follow-up after delivery.

Sections du résumé

Background & Aims UNASSIGNED
Although worsening liver-related symptoms during pregnancy can occur in primary sclerosing cholangitis (PSC), there are insufficient data to effectively counsel patients on their pre-conception risk and no clear recommendations on monitoring and management during pregnancy. We aimed to describe maternal liver-related symptoms in pregnancy, both before and after PSC diagnosis, and explore factors associated with worsening symptoms and liver-related outcomes.
Methods UNASSIGNED
We conducted a multicentre retrospective observational study of females with PSC and known pregnancy with live birth, via the International PSC Study Group. We included 450 patients from 12 European centres. Data included clinical variables, liver-related symptoms (pruritus and/or cholangitis) during pregnancy, and liver biochemistry. A composite primary endpoint of transplant-free survival from time of PSC diagnosis was used.
Results UNASSIGNED
There were 266 pregnancies in 178 patients following PSC diagnosis. Worsening liver-related symptoms were reported in 66/228 (28.9%) pregnancies; they had a reduced transplant-free survival (
Conclusions UNASSIGNED
Liver-related symptoms are frequently encountered during pregnancies before the diagnosis of PSC, and pregnancy may expose the pre-clinical phase of PSC in some patients. Worsening liver-related symptoms were seen in a third of our cohort with known PSC during pregnancy; and this subgroup had a poorer prognosis, which may be related to more advanced liver disease at time of pregnancy and/or a more severe disease phenotype.
Impact and implications UNASSIGNED
Patients with PSC can develop worsening of their liver-related symptoms during pregnancy; however, risk factors for this and the long-term implications are not known. We identified that there is a significant risk of these symptoms in pregnancy, both before and after PSC has been diagnosed, particularly in patients with elevated alkaline phosphatase. Furthermore, our findings suggest that worsening symptoms during pregnancy may be associated with adverse long-term clinical outcomes of liver transplantation and death in patients with known PSC. This may be related to the presence of more advanced liver disease at time of pregnancy. This information can be used to counsel patients with PSC before conception and identify patients who need close follow-up after delivery.

Identifiants

pubmed: 38089547
doi: 10.1016/j.jhepr.2023.100951
pii: S2589-5559(23)00282-3
pmc: PMC10711472
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100951

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors have no relevant disclosures. Please refer to the accompanying ICMJE disclosure forms for further details.

Auteurs

Jeremy S Nayagam (JS)

Institute of Liver Studies, King's College Hospital, London, UK.
Department of Inflammation Biology, King's College London, London, UK.

Tobias J Weismüller (TJ)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
Department of Internal Medicine - Gastroenterology and Oncology, Vivantes-Humboldt-Klinikum, Berlin, Germany.

Piotr Milkiewicz (P)

Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.
Translational Medicine Group, Pomeranian Medical University, Szczecin, Poland.

Karolina M Wronka (KM)

Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.

Emil Bik (E)

Liver and Internal Medicine Unit, Medical University of Warsaw, Warsaw, Poland.

Christoph Schramm (C)

. Department of Medicine and Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Katja Fuessel (K)

. Department of Medicine and Martin Zeitz Center for Rare Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Taotao Zhou (T)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Johannes Chang (J)

Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Martti Färkkilä (M)

European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Clinic of Gastroenterology, Helsinki University Hospital, Helsinki, Finland.

Ylva Carlsson (Y)

Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Anastasia Lundman (A)

Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Nora Cazzagon (N)

European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Unit of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova, Padova, Italy.

Giorgia Corrà (G)

European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Unit of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University Hospital of Padova, Padova, Italy.

Eirini Rigopoulou (E)

Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.

George N Dalekos (GN)

European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa, Greece.

Aiva Lundberg Båve (AL)

Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Annika Bergquist (A)

Department of Medicine Huddinge, Unit of Gastroenterology and Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.

Karim Ben Belkacem (K)

Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, Saint-Antoine Hospital, Assistance Publique-Hôpitaux De Paris, Paris, France.

Marco Marzioni (M)

Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Ancona, Italy.

Martina Mancinelli (M)

Clinic of Gastroenterology and Hepatology, Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Ancona, Italy.

Xavier Verhelst (X)

European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium.

Hanns-Ulrich Marschall (HU)

European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Michael A Heneghan (MA)

Department of Inflammation Biology, King's College London, London, UK.
European Reference Network for Hepatological Diseases (ERN RARE-LIVER), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Deepak Joshi (D)

Institute of Liver Studies, King's College Hospital, London, UK.
Department of Inflammation Biology, King's College London, London, UK.

Classifications MeSH